# Immuneering (IMRX) — Earnings

IMRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$0.38 |
| EPS estimate | −$0.39 |
| EPS surprise | +2.14% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Nov 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1790340/000179034025000135/imrx-20250930.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/af207dd7-51d2-bd4b-5ec4-5c7d68f8d86e.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 12, 2025 | −$0.39 | −$0.38 | 2.14% | — | — |
| Q2 2025 | Aug 13, 2025 | −$0.40 | −$0.40 | 0.07% | — | — |
| Q1 2025 | May 5, 2025 | −$0.53 | −$0.42 | 20.26% | — | — |
| Q4 2024 | Mar 20, 2025 | −$0.42 | −$0.58 | -39.42% | — | — |
| Q3 2024 | Nov 13, 2024 | −$0.55 | −$0.49 | 11.22% | — | — |
| Q2 2024 | Aug 6, 2024 | −$0.52 | −$0.47 | 9.62% | — | — |
| Q1 2024 | May 7, 2024 | −$0.50 | −$0.49 | 2.57% | — | — |
| Q4 2023 | Mar 1, 2024 | −$0.46 | −$0.52 | -12.34% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.49 | −$0.43 | 12.03% | — | — |
| Q2 2023 | Aug 3, 2023 | −$0.53 | −$0.43 | 18.48% | — | — |
| Q1 2023 | May 4, 2023 | −$0.54 | −$0.51 | 5.78% | $8,333.00 | — |
| Q4 2022 | Mar 6, 2023 | −$0.56 | −$0.50 | 10.94% | $60,000.00 | $456.00 |
| Q3 2022 | Nov 10, 2022 | −$0.48 | −$0.49 | -2.08% | $153,333.00 | $38,380.00 |
| Q2 2022 | Aug 10, 2022 | −$0.51 | −$0.44 | 14.21% | $196,800.00 | $94,419.00 |
| Q1 2022 | May 10, 2022 | −$0.44 | −$0.49 | -11.80% | $182,000.00 | $183,698.00 |
| Q4 2021 | Mar 10, 2022 | −$0.39 | −$0.42 | -8.81% | $535,500.00 | $189,591.00 |
| Q3 2021 | Nov 9, 2021 | −$0.56 | −$0.47 | 16.44% | $700,000.00 | $482,130.00 |
| Q2 2021 | Sep 9, 2021 | −$1.66 | −$1.61 | 2.72% | $725,000.00 | $660,040.00 |

## Frequently Asked Questions

### When did Immuneering (IMRX) last report earnings?

Immuneering last reported on Nov 12, 2025, covering fiscal Q3 2025.

### Did IMRX beat earnings estimates?

Yes. Immuneering reported EPS of −$0.38 for Q3 2025 against a −$0.39 estimate — a 2.14% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).